Examination of multiple myeloma prognosis predictive biomarkers based on analysis of PD-1 polymorphisms

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K19190
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Laboratory medicine
• Research Institution: Gunma University
• Principal Investigator: Kasamatsu Tetsuhiro 群馬大学, 大学院保健学研究科, 助教 (60737542)
• Research Collaborator: MURAKAMI hirokazu ; SAITOH takayuki
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: 多発性骨髄腫 / PD-1 / 遺伝子多型

Outline of Final Research Achievements

We investigated the impact of PDCD1 (3 single nucleotide polymorphisms; SNPs), PDCD1LG1 (2 SNPs), CTLA4 (4 SNPs), IDO1 (1 SNPs) and IDO2 (1 SNPs) polymorphisms on susceptibility and clinical features of multiple myeloma (MM) patients.
The PDCD1 high-expression type and IDO2 high-activity type were associated with the susceptibility of MM. In addition, the higher frequencies of patients with CTLA4 and PDCDLG1 high-expression types were observed in more malignant clinical variables. However, there were no significant differences between all polymorphisms and overall survival.

Free Research Field

血液検査学

Academic Significance and Societal Importance of the Research Achievements

本研究成果は、当初期待したPD-1遺伝子多型の多発性骨髄腫患者の予後予測バイオマーカ―としての有効性を認められなかった。しかしながら、PD-1をはじめとした免疫チェックポイント分子の遺伝子多型が多発性骨髄腫の発症やより重症な症状への関係性することが認められ、腫瘍に対する免疫を抑制的に調節する分子の遺伝的な背景が、まだ明らかとされていない多発性骨髄腫の発症および進行のメカニズムに何らかの影響を与えることが解明された。